About Rein Therapeutics Inc.
http://www.reintx.comRein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases.
CEO
James Brian Windsor
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-11-11 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
VOSS CAPITAL, LLC
Shares:2.67M
Value:$2.99M
BIOS CAPITAL MANAGEMENT, LP
Shares:1.69M
Value:$1.89M
VANGUARD GROUP INC
Shares:1.17M
Value:$1.31M
Summary
Showing Top 3 of 42
About Rein Therapeutics Inc.
http://www.reintx.comRein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $5.49M ▼ | $-5.58M ▲ | 0% | $-0.21 ▲ | $-5.58M ▲ |
| Q2-2025 | $0 | $6.87M ▲ | $-6.82M ▼ | 0% | $-0.28 ▲ | $-6.87M ▼ |
| Q1-2025 | $0 | $5.61M ▼ | $-5.5M ▲ | 0% | $-2.51K ▼ | $-5.61M ▲ |
| Q4-2024 | $0 | $5.8M ▼ | $-40.98M ▼ | 0% | $-1.89 ▼ | $-42.52M ▼ |
| Q3-2024 | $0 | $6.07M | $-5.85M | 0% | $-0.27 | $-5.85M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $4.05M ▼ | $53.71M ▼ | $7.52M ▼ | $46.19M ▲ |
| Q2-2025 | $5.72M ▼ | $57.48M ▼ | $54.47M ▲ | $3.01M ▼ |
| Q1-2025 | $7.43M ▼ | $57.63M ▼ | $52.75M ▲ | $4.87M ▼ |
| Q4-2024 | $12.87M ▼ | $69.24M ▼ | $14.85M ▼ | $54.39M ▲ |
| Q3-2024 | $17.65M | $104.22M | $53.99M | $50.23M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-5.58M ▲ | $-3.55M ▲ | $0 | $1.9M ▼ | $-1.67M ▲ | $-3.55M ▲ |
| Q2-2025 | $-6.82M ▼ | $-6.42M ▼ | $0 | $4.71M ▲ | $-1.71M ▲ | $-6.42M ▼ |
| Q1-2025 | $-5.5M ▲ | $-6.17M ▼ | $0 | $738K ▲ | $-5.44M ▼ | $-6.17M ▼ |
| Q4-2024 | $-40.98M ▼ | $-4.81M ▼ | $0 | $1K ▲ | $-4.81M ▼ | $-4.81M ▼ |
| Q3-2024 | $-5.85M | $-3.82M | $0 | $-446K | $-4.26M | $-3.82M |
CEO
James Brian Windsor
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-11-11 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
VOSS CAPITAL, LLC
Shares:2.67M
Value:$2.99M
BIOS CAPITAL MANAGEMENT, LP
Shares:1.69M
Value:$1.89M
VANGUARD GROUP INC
Shares:1.17M
Value:$1.31M
Summary
Showing Top 3 of 42